RPAM
AEGR

Rhenman & Partners Asset Management’s Aegerion Pharmaceuticals AEGR Stock Holding History

Rhenman & Partners Asset Management’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-65,000
Closed -$2.17M – 103
2014
Q3 		$2.17M Buy
65,000
+23,069
+55% +$716K 0.64% 59
2014
Q2 		$1.35M Sell
41,931
-26,464
-39% -$985K 0.4% 77
2014
Q1 		$3.15M Sell
68,395
-6,605
-9% -$387K 0.95% 38
2013
Q4 		$5.32M Buy
+75,000
New +$5.74M 2.08% 11

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Rhenman & Partners Asset Management's AEGR Position: Q4 2014 in Review

Rhenman & Partners Asset Management sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2014, closing a stake of 65,000 shares — an estimated $2.17M sold.

Rhenman & Partners Asset Management first reported a position in AEGR in Q4 2013 and held it in 4 quarters. The position peaked at $5.32M in Q4 2013. 95 funds tracked by Wall St. Rank hold AEGR as of Q4 2014.

  • Rhenman & Partners Asset Management reported no remaining Aegerion Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 65,000 Aegerion Pharmaceuticals shares in Q4 2014, an estimated $2.17M.
  • Rhenman & Partners Asset Management first reported a position in Aegerion Pharmaceuticals in Q4 2013 and held it in 4 quarters.
  • Rhenman & Partners Asset Management's Aegerion Pharmaceuticals position peaked at $5.32M in Q4 2013.
  • 95 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2014.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2014, filed 9 Feb 2015.